U.S. Tumor Markers Testing Market, 2019-2023: Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Tests, Technologies and Opportunities

This new report is a study of the major business opportunities emerging in the U.S. cancer diagnostics market during the next five years. The report examines trends in the U.S. cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

U.S. Market Overview

- Five-year test volume and sales projections.

- Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.

- Estimated universe of laboratories performing cancer diagnostic testing.

- Cancer statistics, etiology and recent developments.

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Test

- Biochemical Markers
- Oncogenes
- Growth Factors
- Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains, and others.

- ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

- Sales and market shares of major cancer diagnostic product suppliers by individual test.

- Five-year test volume and sales forecasts for major tumor markers by market segment, including:

- Hospitals
- Commercial/Private Laboratories
- Physician Offices/Group Practices
- Cancer Clinics

Instrumentation Review

- Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

- Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing.

- Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

- Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

- Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

- The companies analyzed in the report include:

- Abbott
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Clinical Genomics
- Decode Genetics
- DiaSorin
- Diazyme
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic
- Janssen Diagnostics
- Leica Biosystems
- Kyowa Medex
- Myriad Genetics
- OncoLab
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- PerkinElmer
- Polymedco
- Qiagen
- Quest Diagnostics
- Roche
- Scienion
- Sequenom
- Siemens Healthineers
- Takara Bio
- Theradiag
- Thermo Fisher
- Tosoh
- Vermillion
- Wako Pure Chemicals



I. Introduction
II. Worldwide Market Overview
1. Market Overview
2. Worldwide Market Structure
3. Worldwide Market Size and Growth
III. Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
VI. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
(continues)

VII. Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current And Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
(continues)
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src
28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha
(continues)

29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
(continues)
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opioid Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92
(continues)
- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
E. Personal Testing
(continues)
VIII. USA Cancer Diagnostics Market
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Test Volume and Sales Forecasts by Market Segment,
Major Supplier Sales and Market Shares by Test
IX. Competitive Profiles
- Abbott
- AdnaGen/Alere
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Correlogic Systems/Vermillion
- Decode Genetics
- Diadexus
- Diagnocure
- Diasorin
- Eiken Chemical
- Elitech Group
- Enterix
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic/Gen-Probe
- Kreatech/Leica
- Kyowa Medex
- Mackay Life Sciences
- Myriad Genetics
- OncoLab
(continues)
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Quest Diagnostics
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Tosoh
- Thermo
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zila

X. Appendix: Major Universities and Research
Centers Developing Cancer Diagnostic
Technologies and Applications

List Of Tables



Tumor Marker Classification
Major Companies Developing or Marketing
ACTH Tests
Major Companies Developing or Marketing
AFP Tests
Major Companies Developing or Marketing
Beta-2 Microglobulin Tests
Major Companies Developing or Marketing
CA 15-3/27.29 Tests
Major Companies Developing or Marketing
CA 19-9 Tests
Major Companies Developing or Marketing
CA 125 Tests
Major Companies Developing or Marketing
Calcitonin Tests
Major Companies Developing or Marketing
CEA Tests
Major Companies Developing or Marketing
Estrogen Receptor Tests
Major Companies Developing or Marketing
Progesterone Receptor Tests
Major Companies Developing or Marketing
Ferritin Tests
Major Companies Developing or Marketing
Gastrin Tests
(continues)
Major Companies Developing or Marketing
HCG Tests

Major Companies Developing or Marketing
Insulin Tests

Major Companies Developing or Marketing
NSE Tests
Major Companies Developing or Marketing
Occult Blood Tests
Major Companies Developing or Marketing
PAP Smear/HPV Tests
Major Companies Developing or Marketing
PAP Tests
Major Companies Developing or Marketing
PSA Tests
Major Companies Developing or Marketing
Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications
In Cancer Diagnosis
Oncogenes Potential Applications
In Cancer Diagnosis
Major Companies Developing or Marketing
Oncogene Tests
Growth Factors Potential Applications
In Cancer Diagnosis
Colony Stimulating Factors Potential
Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
(continues)
Immunohistochemical Stains Potential
Applications in Cancer Diagnosis

Executive Summary Table: U.S., Total Tumor
Marker Test Volume and Sales Forecast
By Market Segment
U.S., Estimated New Cancer Cases and Deaths

U.S., Estimated Cancer Death Rates
Per 100,000 Population
U.S., Laboratories Performing Tumor
Marker Tests by Market Segment
U.S., Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
U.S., Commercial/Private Laboratories
Performing Tumor Marker Tests
By Annual Test Volume
U.S., Physician Office Laboratories
Performing Tumor Marker Tests
By Practice Size
U.S., Total Tumor Marker Test Volume
Forecast by Market Segment

U.S., All Market Segments Major
Tumor Marker Test Volume Forecast
U.S., Hospital Laboratories Major Tumor
Marker Test Volume Forecast by Test
U.S., Commercial/Private Laboratories
Major Tumor Marker Test Volume Forecast
U.S., Physician Offices/Group Practices
Major Tumor Marker Test Volume Forecast
U.S., Cancer Clinics Major Tumor
Marker Test Volume Forecast by Test
(continues)
U.S., Total Tumor Marker Sales
Forecast by Market Segment
U.S., All Market Segment Major Tumor
Marker Sales Forecast by Test
U.S., Hospital Laboratories Major Tumor
Marker Sales Forecast by Test
U.S., Commercial/Private Laboratories
Major Tumor Marker Sales Forecast by Test
U.S., Physician Offices/Group Practices
Major Tumor Marker Sales Forecast by Test
U.S., Cancer Clinics Major Tumor
Marker Sales Forecast by Test
U.S., ACTH Test Volume and Diagnostics
Sales Forecast by Market Segment

U.S., AFP Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Beta-2 Microglobulin Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S., CA 15-3/27.29 Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S., CA 19-9 Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., CA-125 Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Calcitonin Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S., Cathepsin Test Volume and Diagnostics
Sales Forecast by Market Segment
(continues)
U.S., CEA Test Volume and Diagnostics
Sales by Market Segment
U.S., Chromogranin Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S., Colon-specific Antigen Test Volume
And Diagnostics Sales Forecast by Market Segment
U.S., Cytokeratins Test Volume
And Diagnostics Sales Forecast by Market Segment
U.S., Estrogen Receptor Test Volume
And Diagnostics Sales Forecast by Market Segment

U.S., Ferritin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Gastrin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., HCG Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Insulin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Interferons Test Volume
And Diagnostics Sales Forecast by Market
Segment
U.S., Interleukins Test Volume
And Diagnostics Sales Forecast
by Market Segment
U.S., Lymphocyte Subtyping Test Volume and
Diagnostics Sales Forecast by Market Segment
U.S., NSE Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Nucleolar Test Volume and Diagnostics
Sales Forecast by Market Segment
(continues)
U.S., Occult Blood Test Volume
And Diagnostics Sales Forecast by Market Segment
U.S., Oncogenes Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Pancreatic Oncofetal Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., PAP Smear Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Parathyroid Hormone
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Progesterone Receptor
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., PAP Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., PSA Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., S-100 Protein Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.S., Serotonin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Sialic Acid Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Squamous Cell Carcinoma Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment
(continues)
U.S., TDT Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Thymidine Kinase
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Thyroglobulin Test
Volume and Diagnostics
Sales Forecast by Market Segment
U.S., TPA Test Volume and Diagnostics
Sales Forecast by Market Segment
U.S., Total Tumor Marker Sales
By Major Supplier
U.S., ACTH Testing Market Diagnostics
Sales by Major Supplier
U.S., AFP Testing Market Diagnostics
Sales by Major Supplier
U.S., Beta-2 Migroblolulin Testing Market Diagnostics
Sales by Major Supplier
U.S., CA 15-3/27.29 Testing Market Diagnostics
Sales by Major Supplier
U.S., CA 19-9 Testing Market Diagnostics
Sales by Major Supplier
U.S., CA 125 Testing Market Diagnostics
Sales by Major Supplier
U.S., CEA Testing Market Diagnostics
Sales by Major Supplier
U.S., Ferritin Testing Market
Diagnostics Sales by Major Supplier
(continues)
U.S., HCG Testing Market
Diagnostics Sales by Major Supplier
U.S., Insulin Testing Market
Diagnostics Sales by Major Supplier
U.S., Parathyroid Hormone Testing Market
Diagnostics Sales by Major Supplier
U.S., PAP Testing Market Diagnostics
Sales by Major Supplier
U.S., Progesterone Receptor Testing Market
Diagnostics Sales by Major Supplier
U.S., PSA Testing Market Diagnostics
Sales by Major Supplier

2024 U.S. Hospital Virology and Bacteriology Testing Market Volume and Sales Segment Forecasts, Emerging Technologies, Instrumentation and Opportunities

This new report contains 997 pages and 87 tables.The report is available by section, and can be customized to specific information needs and budget.The report presents a comprehensive analysis of

USD 3750 View Report

2024 U.S. Hepatitis Diagnostic Testing for 10 Markers Volume and Sales Segment Forecasts for Immunodiagnostic and Molecular Diagnostic Procedures--Hospitals, Blood Banks, Commercial Labs, POC Locations

The report presents a detailed analysis of the Hepatitis diagnostics market in the US. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report is available

USD 2500 View Report

2024 US Hospital Cancer Diagnostics Market: Supplier Shares by Test, Volume and Sales Segment Forecasts for Major Tumor Markers, Competitive Landscape, Innovative Technologies, Instrumentation Review, Opportunities for Suppliers

This new report from contains 567 pages and 50 tables.The report is available by section, and can be customized to specific information needs and budget.The report presents a comprehensive analysis of

USD 3500 View Report

2024 UK Hospital Cancer Diagnostics Market: Supplier Shares by Test, Volume and Sales Segment Forecasts for Major Tumor Markers, Competitive Landscape, Innovative Technologies, Instrumentation Review, Opportunities for Suppliers

This new report from  contains 527 pages and 37 tables.The report is available by section, and can be customized to specific information needs and budget.The report presents a comprehensive analysis

USD 3500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available